Market Research Logo

Rheumatoid Arthritis - Pipeline Review, H1 2018

Rheumatoid Arthritis - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis - Pipeline Review, H1 2018, provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape.

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 13, 1, 28, 47, 63, 1, 6, 207, 49 and 8 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 4, 32 and 5 molecules, respectively.

Rheumatoid Arthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Rheumatoid Arthritis - Overview
Rheumatoid Arthritis - Therapeutics Development
Rheumatoid Arthritis - Therapeutics Assessment
Rheumatoid Arthritis - Companies Involved in Therapeutics Development
Rheumatoid Arthritis - Drug Profiles
Rheumatoid Arthritis - Dormant Projects
Rheumatoid Arthritis - Discontinued Products
Rheumatoid Arthritis - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Rheumatoid Arthritis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..11), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..12), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..13), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Products under Development by Companies, H1 2018 (Contd..10), H1 2018
Products under Development by Companies, H1 2018 (Contd..11), H1 2018
Products under Development by Companies, H1 2018 (Contd..12), H1 2018
Products under Development by Companies, H1 2018 (Contd..13), H1 2018
Products under Development by Companies, H1 2018 (Contd..14), H1 2018
Products under Development by Companies, H1 2018 (Contd..15), H1 2018
Products under Development by Companies, H1 2018 (Contd..16), H1 2018
Products under Development by Companies, H1 2018 (Contd..17), H1 2018
Products under Development by Companies, H1 2018 (Contd..18), H1 2018
Products under Development by Companies, H1 2018 (Contd..19), H1 2018
Products under Development by Companies, H1 2018 (Contd..20), H1 2018
Products under Development by Companies, H1 2018 (Contd..21), H1 2018
Products under Development by Companies, H1 2018 (Contd..22), H1 2018
Products under Development by Companies, H1 2018 (Contd..23), H1 2018
Products under Development by Universities/Institutes, H1 2018
Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Rheumatoid Arthritis - Pipeline by 3SBio Inc, H1 2018
Rheumatoid Arthritis - Pipeline by 4D Pharma PLC, H1 2018
Rheumatoid Arthritis - Pipeline by AB Science SA, H1 2018
Rheumatoid Arthritis - Pipeline by AbbVie Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Ablynx NV, H1 2018
Rheumatoid Arthritis - Pipeline by ACEA Biosciences Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Aclaris Therapeutics Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Adello Biologics LLC, H1 2018
Rheumatoid Arthritis - Pipeline by Alteogen Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Amarna Therapeutics BV, H1 2018
Rheumatoid Arthritis - Pipeline by Amgen Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Applied Genetic Technologies Corp, H1 2018
Rheumatoid Arthritis - Pipeline by Aptevo Therapeutics Inc, H1 2018
Rheumatoid Arthritis - Pipeline by arGentis Pharmaceuticals LLC, H1 2018
Rheumatoid Arthritis - Pipeline by Arrien Pharmaceuticals LLC, H1 2018
Rheumatoid Arthritis - Pipeline by Arthrogen BV, H1 2018
Rheumatoid Arthritis - Pipeline by Asahi Kasei Pharma Corp, H1 2018
Rheumatoid Arthritis - Pipeline by Astellas Pharma Inc, H1 2018
Rheumatoid Arthritis - Pipeline by AstraZeneca Plc, H1 2018
Rheumatoid Arthritis - Pipeline by Atlantic Bio Sci LLC, H1 2018
Rheumatoid Arthritis - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Axsome Therapeutics Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Axxam SpA, H1 2018
Rheumatoid Arthritis - Pipeline by Baliopharm AG, H1 2018
Rheumatoid Arthritis - Pipeline by Bayer AG, H1 2018
Rheumatoid Arthritis - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Biocad, H1 2018
Rheumatoid Arthritis - Pipeline by Biocon Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Biogen Inc, H1 2018
Rheumatoid Arthritis - Pipeline by BioLingus AG, H1 2018
Rheumatoid Arthritis - Pipeline by BioLite Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Biozeus Pharmaceutical SA, H1 2018
Rheumatoid Arthritis - Pipeline by Bird Rock Bio Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Rheumatoid Arthritis - Pipeline by Bristol-Myers Squibb Co, H1 2018
Rheumatoid Arthritis - Pipeline by BTB Pharma AB, H1 2018
Rheumatoid Arthritis - Pipeline by Can-Fite BioPharma Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Cardax Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Carna Biosciences Inc, H1 2018
Rheumatoid Arthritis - Pipeline by CASI Pharmaceuticals Inc, H1 2018
Rheumatoid Arthritis - Pipeline by CEL-SCI Corp, H1 2018
Rheumatoid Arthritis - Pipeline by Celgene Corp, H1 2018
Rheumatoid Arthritis - Pipeline by Celltrion Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Chipscreen Biosciences Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by ChironWells GmbH, H1 2018
Rheumatoid Arthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Rheumatoid Arthritis - Pipeline by CJ HealthCare Corp, H1 2018
Rheumatoid Arthritis - Pipeline by Clevexel Pharma SAS, H1 2018
Rheumatoid Arthritis - Pipeline by Coherus BioSciences Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Commence Bio Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Compugen Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Crossject SA, H1 2018
Rheumatoid Arthritis - Pipeline by CSL Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Cyxone AB, H1 2018
Rheumatoid Arthritis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Diamyd Medical AB, H1 2018
Rheumatoid Arthritis - Pipeline by Diurnal Group Plc, H1 2018
Rheumatoid Arthritis - Pipeline by Domainex Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Ducentis BioTherapeutics Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Eisai Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Enceladus Pharmaceuticals BV, H1 2018
Rheumatoid Arthritis - Pipeline by Enzene Biosciences Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Fountain Biopharma Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Fresenius SE & Co KGaA, H1 2018
Rheumatoid Arthritis - Pipeline by Fujifilm Holdings Corporation, H1 2018
Rheumatoid Arthritis - Pipeline by Galapagos NV, H1 2018
Rheumatoid Arthritis - Pipeline by Gene Techno Science Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Genentech Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Genfit SA, H1 2018
Rheumatoid Arthritis - Pipeline by Genor BioPharma Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Genosco Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Gilead Sciences Inc, H1 2018
Rheumatoid Arthritis - Pipeline by GlaxoSmithKline Plc, H1 2018
Rheumatoid Arthritis - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Han Wha Pharma Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Hansa Medical AB, H1 2018
Rheumatoid Arthritis - Pipeline by Hanwha Chemical Corp, H1 2018
Rheumatoid Arthritis - Pipeline by HitGen LTD, H1 2018
Rheumatoid Arthritis - Pipeline by Huabo Biopharm Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Hualan Biological Engineering Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Hutchison MediPharma Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by ID Pharma Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Idogen AB, H1 2018
Rheumatoid Arthritis - Pipeline by Immune Response BioPharma Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Immungenetics AG, H1 2018
Rheumatoid Arthritis - Pipeline by ImmunoFrontier Inc, H1 2018
Rheumatoid Arthritis - Pipeline by ImmunoPrecise Antibodies Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Immunwork Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Innate Pharma SA, H1 2018
Rheumatoid Arthritis - Pipeline by Innovent Biologics Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Intas Pharmaceuticals Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Istesso Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Japan Tobacco Inc, H1 2018
Rheumatoid Arthritis - Pipeline by JHL Biotech Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Johnson & Johnson, H1 2018
Rheumatoid Arthritis - Pipeline by Jyant Technologies Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Kadmon Corp LLC, H1 2018
Rheumatoid Arthritis - Pipeline by KAHR medical Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Kang Stem Biotech Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by KBP BioSciences Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Kezar Life Sciences Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Lead Pharma Holding BV, H1 2018
Rheumatoid Arthritis - Pipeline by LG Chem Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Lipocure Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Livzon Pharmaceutical Group Inc, H1 2018
Rheumatoid Arthritis - Pipeline by LSK BioPartners Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Lupin Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Mabion SA, H1 2018
Rheumatoid Arthritis - Pipeline by mAbxience SA, H1 2018
Rheumatoid Arthritis - Pipeline by Maruho Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Mebiopharm Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by MedAnnex Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by MedImmune LLC, H1 2018
Rheumatoid Arthritis - Pipeline by Merck & Co Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Merck KGaA, H1 2018
Rheumatoid Arthritis - Pipeline by Mesoblast Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Rheumatoid Arthritis - Pipeline by Momenta Pharmaceuticals Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Morphotek Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Mycenax Biotech Inc, H1 2018
Rheumatoid Arthritis - Pipeline by MYOS RENS Technology Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Navigen Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Nissan Chemical Industries Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Nordic Group BV, H1 2018
Rheumatoid Arthritis - Pipeline by Novartis AG, H1 2018
Rheumatoid Arthritis - Pipeline by NovelMed Therapeutics Inc, H1 2018
Rheumatoid Arthritis - Pipeline by NovImmune SA, H1 2018
Rheumatoid Arthritis - Pipeline by Nuevolution AB, H1 2018
Rheumatoid Arthritis - Pipeline by Numab Innovation AG, H1 2018
Rheumatoid Arthritis - Pipeline by Omeros Corp, H1 2018
Rheumatoid Arthritis - Pipeline by Oncodesign SA, H1 2018
Rheumatoid Arthritis - Pipeline by OncoImmune Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by OSE Immunotherapeutics, H1 2018
Rheumatoid Arthritis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2018
Rheumatoid Arthritis - Pipeline by Peptinov SAS, H1 2018
Rheumatoid Arthritis - Pipeline by Pfizer Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Pharmedartis GmbH, H1 2018
Rheumatoid Arthritis - Pipeline by Philogen SpA, H1 2018
Rheumatoid Arthritis - Pipeline by PlantForm Corp, H1 2018
Rheumatoid Arthritis - Pipeline by PLx Pharma Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Principia Biopharma Inc, H1 2018
Rheumatoid Arthritis - Pipeline by ProNoxis AB, H1 2018
Rheumatoid Arthritis - Pipeline by Protab Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Protalex Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Protheragen Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Qilu Pharmaceutical Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Qu Biologics Inc, H1 2018
Rheumatoid Arthritis - Pipeline by R Pharm, H1 2018
Rheumatoid Arthritis - Pipeline by ReceptoPharm Inc, H1 2018
Rheumatoid Arthritis - Pipeline by RedHill Biopharma Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Resverlogix Corp, H1 2018
Rheumatoid Arthritis - Pipeline by ReveraGen BioPharma Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Rhizen Pharmaceuticals SA, H1 2018
Rheumatoid Arthritis - Pipeline by Ribomic Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Richter Gedeon Nyrt, H1 2018
Rheumatoid Arthritis - Pipeline by Rottapharm Biotech Srl, H1 2018
Rheumatoid Arthritis - Pipeline by Saje Pharma LLC, H1 2018
Rheumatoid Arthritis - Pipeline by Sandoz International GmbH, H1 2018
Rheumatoid Arthritis - Pipeline by Sareum Holdings Plc, H1 2018
Rheumatoid Arthritis - Pipeline by SBI Biotech Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Shanghai Henlius Biotech Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Simcere Pharmaceutical Group, H1 2018
Rheumatoid Arthritis - Pipeline by Synermore Biologics Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Teijin Pharma Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by TheraMAB LLC, H1 2018
Rheumatoid Arthritis - Pipeline by Tiziana Life Sciences Plc, H1 2018
Rheumatoid Arthritis - Pipeline by Toleranzia AB, H1 2018
Rheumatoid Arthritis - Pipeline by TTY Biopharm Company Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Tumorend LLC, H1 2018
Rheumatoid Arthritis - Pipeline by Twoxar Inc, H1 2018
Rheumatoid Arthritis - Pipeline by TxCell SA, H1 2018
Rheumatoid Arthritis - Pipeline by UCB SA, H1 2018
Rheumatoid Arthritis - Pipeline by United BioPharma Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Vaccinex Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Valeant Pharmaceuticals International Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Vicore Pharma AB, H1 2018
Rheumatoid Arthritis - Pipeline by X-Rx Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Xbrane Biopharma AB, H1 2018
Rheumatoid Arthritis - Pipeline by XL-protein GmbH, H1 2018
Rheumatoid Arthritis - Pipeline by YiChang Humanwell Pharmaceutical Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Yungjin Pharm Co Ltd, H1 2018
Rheumatoid Arthritis - Pipeline by Yuyu Pharma Inc, H1 2018
Rheumatoid Arthritis - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..1), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..2), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..3), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..4), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..5), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..6), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..7), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..8), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..9), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..10), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..11), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..12), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..13), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..14), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..15), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..16), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..17), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..18), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..19), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..20), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..21), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..22), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..23), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..24), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..25), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..26), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..27), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..28), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..29), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..30), H1 2018
Rheumatoid Arthritis - Dormant Projects, H1 2018 (Contd..31), H1 2018
Rheumatoid Arthritis - Discontinued Products, H1 2018
Rheumatoid Arthritis - Discontinued Products, H1 2018 (Contd..1), H1 2018
Rheumatoid Arthritis - Discontinued Products, H1 2018 (Contd..2), H1 2018
Rheumatoid Arthritis - Discontinued Products, H1 2018 (Contd..3), H1 2018
Rheumatoid Arthritis - Discontinued Products, H1 2018 (Contd..4), H1 2018
Rheumatoid Arthritis - Discontinued Products, H1 2018 (Contd..5), H1 2018
Rheumatoid Arthritis - Discontinued Products, H1 2018 (Contd..6), H1 2018
List of Figures
Number of Products under Development for Rheumatoid Arthritis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report